ReFacto AF
moroctocog alfa
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for ReFacto AF. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for ReFacto AF.
-
List item
ReFacto AF : EPAR - Summary for the public (PDF/78.12 KB)
First published: 05/05/2009
Last updated: 29/09/2016 -
-
List item
ReFacto AF : EPAR - Risk-management-plan summary (PDF/1.17 MB)
First published: 13/05/2020
Authorisation details
Product details | |
---|---|
Name |
ReFacto AF
|
Agency product number |
EMEA/H/C/000232
|
Active substance |
moroctocog alfa
|
International non-proprietary name (INN) or common name |
moroctocog alfa
|
Therapeutic area (MeSH) |
Hemophilia A
|
Anatomical therapeutic chemical (ATC) code |
B02BD02
|
Publication details | |
---|---|
Marketing-authorisation holder |
Pfizer Europe MA EEIG
|
Revision |
40
|
Date of issue of marketing authorisation valid throughout the European Union |
13/04/1999
|
Contact address |
Boulevard de la Plaine 17 |
Product information
08/11/2022 ReFacto AF - EMEA/H/C/000232 - N/0166
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antihemorrhagics
Therapeutic indication
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor-VIII deficiency).
ReFacto AF is appropriate for use in adults and children of all ages, including newborns.
ReFacto AF does not contain von-Willebrand factor, and hence is not indicated in von-Willebrand's disease.